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(57) ABSTRACT 
The present disclosure provides ex vivo-derived mineralized 
three-dimensional bone constructs. The bone constructs are 
obtained by culturing osteoblasts and osteoclast precursors 
under randomized gravity vector conditions. Preferably, the 
randomized gravity vector conditions are obtained using a 
low shear stress rotating bioreactor, such as a High Aspect 
Ratio Vessel (HARV) culture system. The bone constructs of 
the disclosure have utility in physiological studies of bone 
formation and bone function, in drug discovery, and in ortho-
pedics. 
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MINERALIZED THREE-DIMENSIONAL 	 load interventions, have limited utility due to the lack of 
BONE CONSTRUCTS 	 similarity to the true physiological state existing within bone 
tissue in vivo. 
This application is a divisional of U.S. patent application 
Ser. No. 11/693,662 filed Mar. 29, 2007, which in turn claims 
the benefit of U.S. Provisional Patent Application Ser. No. 
60/787,431, filed Mar. 30, 2006, each of which is incorpo-
rated herein by reference in its entirety. 
The U.S. Government has a paid-up license in this inven-
tion and the right in limited circumstances to require the 
patent owners to license others on reasonable terms as pro-
vided for by the terms of Contract No. NNJ04HF46H 
awarded by the National Aeronautics and Space Administra-
tion (NASA). 
FIELD OF THE INVENTION 
The invention relates to ex vivo-derived mineralized three-
dimensional bone constructs which replicate natural bone. 
BACKGROUND 
One of the central problems associated with studying both 
the normal and pathophysiology of bone is that as an organ 
system it is slow growing and the time to show an observable 
response to a particular stimulus is relatively long. The nature 
of the mineralized tissue matrix of bone in vivo and its com-
plex architecture also presents several technical problems 
associated with how experimental observations can be made. 
At present, truly informative studies designed to understand 
bone physiology have relied primarily on the removal of 
samples of bone tissue from normal or diseased tissue either 
in a clinical setting or from experimental animal models. 
To date, there is no three dimensional tissue culture model 
of bone, either of animal or human origin. The prior art has 
relied primarily on the use of monotype cell type cultures of 
osteoblasts or osteoclast cells grown on planar, two dimen-
sional tissue culture surfaces. Such cultures have also been 
grown in three dimensional collagen support gels and some 
investigators have utilized culture systems that allow types of 
mechanical strain to be applied to the cells in order to study 
the effects of mechanical loading. However, these cultures 
have been primarily focused on the responses of a single cell 
type, such as osteoblasts, to various environmental stimuli. 
Existing planar monotype tissue culture models of bone do 
not allow the study of the interactions between the different 
cell types present in normal bone responsible for normal bone 
remodeling. The developmentally inactive osteocyte cell type 
present in the mineralized matrix of normal bone in vivo 
(from which osteoblasts are derived) have yet to be fully 
characterized in any tissue culture model due to their sup-
posed transformation into osteoblasts once they have been 
removed from the bone matrix and placed into culture. 
Moreover, the process of mineralization, which is essential 
to the formation of new bone, has previously only been stud-
ied in monotype cultures of osteoblasts. The mineralization 
process has been studied in such models in the absence of the 
major cell type involved in the removal of mineralized mate-
rial, namely the osteoclast. However, the complex interplay 
between both of these cell types is essential for normal bone 
remodeling (i.e. bone formation and bone loss). Without both 
cell types being present, a true in vitro/ex vivo representation 
of the normal or indeed pathological processes involved in the 
bone remodeling process is impossible. As such, the use of 
such monotype culture models to investigate the effects of 
manipulations, such as anti -o steoporetic drugs or mechanical  
5 	 SUMMARY 
In one aspect, the disclosure provides ex vivo-derived min-
eralized three-dimensional bone constructs, each comprising 
a spheroid of between about 200 µm and about 4 mm in 
10 diameter having an outer layer surrounding an inner core. The 
outer layer is comprised of osteoclasts, and the inner layer is 
comprised of osteoblasts, osteocytes, or both osteoblasts and 
osteocytes embedded within a crystalline matrix. The crys- 
15 talline matrix is comprised of calcium, phosphates, and car-
bonates. 
In another aspect, the disclosure provides methods for pro-
ducing mineralized three-dimensional bone constructs. In 
one embodiment, a method comprises introducing osteoclast 
20 precursors and osteoblasts into a culture vessel comprising a 
matrix-free culture medium; culturing the osteoclast precur-
sors and the osteoblasts under randomized gravity vector 
conditions wherein aggregates of the osteoblasts and the 
osteoclast precursors are formed; and introducing a matrix- 
25 free mineralization culture medium into the culture vessel 
and culturing the aggregates under randomized gravity vector 
conditions. 
In another embodiment, a method comprises culturing 
osteoclast precursors and osteoblasts in a matrix-free culture 
30 medium using a low shear rotational three-dimensional tissue 
culture technique under conditions effective to form aggre-
gates comprising the osteoblasts and the osteoclast precur-
sors, and culturing the aggregates using said low shear rota-
tional three-dimensional tissue culture technique in a matrix- 
35 free mineralization culture medium that promotes 
mineralization of said aggregates. 
In another embodiment, a method comprises introducing 
osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal 
4o axis, the cylindrical culture vessel comprising a matrix-free 
culture medium; culturing the osteoblasts and the osteoclast 
precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear 
conditions and to promote the formation of aggregates com- 
45 prising the osteoclast precursors and said osteoblasts; and 
introducing a matrix-free mineralization culture medium into 
the cylindrical culture vessel and culturing the aggregates 
during substantially horizontal rotation at a rate effective to 
create low shear conditions. 
50 In another embodiment, the method comprises introducing 
osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal 
axis, the cylindrical culture vessel comprising a matrix-free 
culture medium; culturing the osteoblasts and the osteoclast 
55 precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear 
conditions and to promote the formation of aggregates com-
prising the osteoclast precursors and said osteoblasts; further 
culturing the aggregates in the cylindrical culture vessel dur- 
60 ing substantially horizontal rotation at a rate effective to cre-
ate low shear conditions so that the aggregates grow in size 
and the osteoclast precursors differentiate into osteoclasts; 
and introducing a matrix-free mineralization culture medium 
into the cylindrical culture vessel and culturing the aggregates 
65 during substantially horizontal rotation at a rate effective to 
create low shear conditions, wherein the mineralized three-
dimensional bone constructs are formed. 
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In another aspect, the disclosure provides a mineralized 
three-dimensional bone construct produced by introducing 
osteoclast precursors and osteoblasts into a cylindrical cul-
ture vessel that rotates about a substantially central horizontal 
axis, the cylindrical culture vessel comprising a matrix-free 
culture medium; culturing the osteoblasts and the osteoclast 
precursors in the cylindrical culture vessel during substan-
tially horizontal rotation at a rate effective to create low shear 
conditions and to promote the formation of aggregates com-
prising the osteoclast precursors and said osteoblasts; further 
culturing the aggregates in the cylindrical culture vessel dur-
ing substantially horizontal rotation at a rate effective to cre-
ate low shear conditions so that the aggregates grow in size 
and the osteoclast precursors differentiate into osteoclasts; 
and introducing a matrix-free mineralization culture medium 
into the cylindrical culture vessel and culturing the aggregates 
during substantially horizontal rotation at a rate effective to 
create low shear conditions, wherein the mineralized three-
dimensional bone constructs are formed. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a flowchart of an example of a method for pre-
paring mineralized three-dimensional bone constructs. 
FIGS. 2A-213 present images of mineralized three-dimen-
sional bone constructs at 14 days of mineralization (FIG. 2A) 
and 21 days of mineralization (FIG. 213). The scale bars each 
represent 1 cm. 
FIGS. 3A-313 present images of mineralized three-dimen-
sional bone constructs. FIG. 3A presents a fluorescence con-
focal microscopy image of an optical section through bone 
constructs in which the osteoclast precursor cells were 
labeled with a fluorescent cell tracking dye (observable as 
white spots in FIG. 3A). FIG. 3B shows the same constructs 
viewed in incident laser light (i.e. non-fluorescent illumina-
tion) to illustrate the shape of the constructs. The scale bar in 
each of FIG. 3A and FIG. 3B is 200 µm. 
FIG. 4 presents a three dimensional reconstruction of a 
large bone construct using Z series confocal imaging. Osteo-
clast precursors were labeled with a fluorescent cell tracking 
dye. Panels A-I in FIG. 4 are the individual images usedby the 
confocal imaging software to build the optical reconstruction 
of the bone construct in three dimensions, each image repre-
senting a sequential view over the surface of the construct 
(white spots indicate individual cells). 
FIGS. 5A-5D show Alizarin red S staining and von Kossa 
staining of sections through a bone construct. FIG. 5A shows 
a 5x magnification image of Alizarin red S staining and FIG. 
5B shows a 20x magnification image of Alizarin red S stain- 
ing (which appears as the dark regions of the images). FIG. 
5C shows a 5x magnification image of von Kossa staining and 
FIG. 5B shows a 20x magnification image of von Kossa 
staining (which appears as the dark regions of the images). 
FIGS. 6A-613 show Harris Hematoxylin staining of sec-
tions through a bone construct. FIG. 6A is a 5x magnification 
image and FIG. 6B is a 20x magnification image. The dark 
regions of the image indicate staining Arrows in FIG. 6B 
point to large numbers of cells embedded within the crystal-
line matrix in the three dimensional construct. 
FIGS. 7A-7C show images of bone construct in which 
osteoclast precursors were labeled with a fluorescent cell 
tracking dye prior to formation of the bone construct, and the 
bone construct was stained with a primary antibody against 
osteocalcein (a marker of osteoclast differentiation) and an 
Alexa 488-labeled secondary antibody. FIG. 7A shows osteo-
calcein staining, FIG. 7B shows CellTracker-Orange stain-
ing, and FIG. 7C shows the same construct illuminated with 
4 
incident laser light. The results indicate that osteocalcein 
staining and cell tracking dye (both visible as a white "ring" 
around the construct in FIGS. 7A and 713) are spatially local-
ized to the same area of the construct. 
5 
DETAILED DESCRIPTION 
In one aspect, the present disclosure provides mineralized 
three-dimensional bone constructs (sometimes referred to 
to herein simply as "bone constructs"). The mineralized three 
dimensional constructs of the disclosure are "bone like" in 
appearance by visual inspection, in certain important respects 
resembling trabecular bone (also known in the art as "spongy 
bone"). In preferred embodiments, the mineralized three- 
15 dimensional bone constructs of the disclosure are macro-
scopic in size and are approximately spheroidal in shape, 
preferably between about 200 µm and about 4 mm in diam-
eter; however, larger and smaller bone constructs are specifi- 
20 cally contemplated. 
The bone constructs comprise an inner core surrounded by 
an outer layer. The inner core comprises a three-dimensional 
crystalline matrix that stains positively with Alizarin Red S 
stain and with the von Kossa histochemical stain, indicating 
25 that it comprises mineral elements observed in normal human 
bone in vivo, including calcium, phosphates, and carbonates. 
The inner core also comprises osteoblasts and/or osteocytes 
embedded within the crystalline matrix, and is preferably 
devoid of necrotic tissue. Osteocytes are developmentally 
so inactive cells found only in native bone tissue in vivo and are 
believed to be formed from osteoblasts that have become 
trapped in the crystalline matrix. The outer layer is comprised 
of osteoclasts, which may express the differentiation marker 
osteocalcein. The cell types in the bone constructs of the 
35 disclosure can be obtained from any mammalian species, but 
are preferably obtained from humans. 
In another aspect, the disclosure provides methods for pro-
ducing the mineralized three-dimensional bone constructs. In 
general, the bone constructs of the disclosure are produced by 
40 culturing osteoclast precursors and osteoblasts together under 
randomized gravity vector conditions (approaching those 
conditions that cultured cells experience during microgravity 
culture) in a matrix-free culture medium. Osteoclast precur-
sors may be obtained from bone marrow and/or peripheral 
45 blood lymphocytes by techniques well known in the art. 
Osteoclast precursors may also be obtained from commercial 
sources (for example, from Cambrex/Loma, Inc.). Osteo-
blasts, preferably primary human osteoblasts, may also be 
obtained by techniques well known in the art, and may also be 
50 obtained from commercial sources (for example, from Pro-
moCell, Inc. and from Cambrex/Loma, Inc.). A "matrix-free 
culture medium" is a cell culture medium which does not 
include carrier material (such as microcarrier beads or col-
lagen gels) onto which osteoblasts and osteoclast precursors 
55 can attach. Suitable cell culture media include Eagle's Mini-
mal Essential Medium (EMEM) or Dulbecco's Modified 
Eagle's Medium (DMEM), preferably supplemented with 
fetal bovine serum (FBS). Preferably, the matrix-free culture 
medium also comprises osteoblast growth supplements such 
6o as ascorbic acid. The matrix-free culture medium preferably 
also further comprises osteoclast differentiation factors, such 
as Receptor Activator of NF-kB (RANK) ligand and mac-
rophage colony stimulating factor (M-CSF). For example, in 
one embodiment the matrix-free culture medium comprises 
65 FBS-supplemented DMEM, ascorbic acid, RANK ligand, 
and M-CSF. Example 2 includes a description of one suitable 
matrix-free culture medium. 
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The osteoclast precursors and the osteoblasts are cultured 
together under randomized gravity vector conditions effec-
tive to achieve the formation of mixed aggregates of the two 
cell types. The aggregates are then further cultured under 
randomized gravity vector conditions to increase the aggre-
gates size and to differentiate the osteoclast precursors into 
mature osteoclasts. 
After a predetermined time, the aggregates are cultured 
under randomized gravity vector conditions in a matrix-free 
mineralization culture medium. A "matrix-free mineraliza-
tion culture medium" is a cell culture medium that includes 
one or more mineralization agents, such as osteoblast differ-
entiation factors, that induce osteoblasts to produce crystal-
line deposits (comprising calcium, phosphate, and carbon-
ates) but which does not include carrier material (such as 
microcarrierbeads and collagen gels) onto which osteoblasts 
and osteoclast precursors can attach. For example, in one 
embodiment, a matrix-free mineralization culture medium 
comprises FBS-supplemented EMEM or DMEM, supple-
mented with the osteoblast differentiation factors. Osteoblast 
differentiation factors include beta-glycerophosphate and 
hydrocortisone-21-hemisuccinate. Preferably, the matrix-
free mineralization culture medium also includes osteoclast 
differentiation factors such as RANK ligand and M-CSF, and 
also includes osteoblast growth supplements such as ascorbic 
acid. For example, in one embodiment the matrix-free min-
eralization culture medium comprises FB S -supplemented 
DMEM, beta-glycerophosphate, ascorbic acid, hydrocorti-
sone-21-hemisuccinate, RANK ligand and M-CSF. Example 
2 includes a description of one suitable matrix-free mineral-
ization medium. 
In preferred embodiments, randomized gravity vector con-
ditions are obtained by culturing osteoclast precursors and 
osteoblasts in a low shear stress rotating bioreactor. Such 
bioreactors were initially designed to mimic some of the 
physical conditions experienced by cells cultured in true 
microgravity during space flight. In general, a low shear stress 
rotating bioreactor comprises a cylindrical culture vessel. 
One or more ports are operatively associated with the lumen 
of the vessel for the introduction and removal of cells and 
culture media. The cylindrical culture vessel is completely 
filled with a culture medium to eliminate head space. The 
cylindrical culture vessel rotates about a substantially central 
horizontal axis. The resulting substantially horizontal rota-
tion occurs at a rate chosen so that (1) there is essentially no 
relative motion between the walls of the vessel and the culture 
medium; and (2) cells remain in suspension within a deter-
mined spatial region of the vessel such that they experience a 
continuous "free fall' through the culture medium at terminal 
velocity with low shear stress and low turbulence. This free 
fall state may be maintained continuously for up to several 
months in some applications described in the prior art. The 
continuous orbital movement of the medium relative to the 
cells also allows for highly efficient transfer of gases and 
nutrients. 
In some embodiments, the diameter of the cylindrical cul-
ture vessel is substantially greater than its height. Such cylin-
drical culture vessels are often referred to in the art as High 
Aspect Ratio Vessels (HARVs). For example, a HARV having 
• volume of 10 mL may have a diameter of about 10 cm and 
• height of about 1 cm. At least a portion of the vessel walls 
may be comprised of a gas permeable membrane to allow gas 
exchange between the culture medium and the surrounding 
incubator environment. A suitable HARV is described in, for 
example, U.S. Pat. No. 5,437,998, incorporated by reference 
6 
herein in its entirety. One commercial embodiment of a 
HARV is the Rotating Cell Culture System (RCCS) available 
from Synthecon, Inc. 
In some embodiments, the diameter of the cylindrical cul- 
5 ture vessel is substantially smaller than its height. Such cylin-
drical culture vessels are often referred to in the art as Slow 
Turning Lateral Vessels (STLVs). STLVs typically have a 
core, comprised of a gas permeable membrane, running 
through the center of the cylinder in order to allow gas 
io exchange between the culture medium and the surrounding 
incubator environment. STLVs are available from Synthecon, 
Inc. 
The use of low shear stressing rotating bioreactor culture 
systems is described in, for example, Nickerson et al., Immu- 
15 nity. 69:7106-7120 (2001); Carterson et al., Infection & 
Immunity. 73(2):1129-40 (2005); and in Goodwin et al. U.S. 
Pat. No. 5,496,722, each of which is specifically incorporated 
herein by reference in its entirety. 
In one embodiment, osteoclast precursors and osteoblasts 
20 are introduced into a cylindrical culture vessel in matrix-free 
culture medium. The osteoclast precursors and the osteo-
blasts may be introduced into the cylindrical culture vessel 
separately, or they may be introduced into the cylindrical 
culture vessel as a pre-mixture of the two cell types. Prefer- 
25 ably, the cells are introduced into the cylindrical culture ves-
sel at a osteoblastosteoclast precursor ratio of from about 2:1 
to about 3:1, although higher and lower ratios are within the 
scope of the disclosure. The absolute number of cells intro-
duced into the cylindrical culture vessel may also be varied. 
3o For example, in some embodiments where a ratio of about 2:1 
is employed, about 2 million osteoblasts and about 1 million 
osteoclast precursors are introduced; in other embodiments 
about 4 million osteoblasts and about 2 million osteoclast 
precursors are introduced; and in still further embodiments 
35 about 8 million osteoblasts and about 4 million osteoclast 
precursors are introduced. The ratio of osteoblasts:osteoclast 
precursors and the absolute number of cells can be varied in 
order to vary the size and the number of aggregates formed. In 
addition, other cell types may also be introduced into the 
40 cylindrical culture vessel. For example, bone marrow stroma 
and stem cells may be cultured along with the osteoblasts and 
the osteoclast precursors. 
One or more cell types may optionally be labeled with a 
cell-tracking marker, such as a fluorescent cell-tracking dye, 
45 prior to their introduction into the cylindrical culture vessel. 
In this way, it is possible to determine the location of the 
individual cell types during, or at the conclusion of, the for-
mation of the bone constructs. For example, fluorescent Cell-
Tracker dyes, available from Invitrogen, Inc., may be used in 
50 conjunction with fluorescence microscopy techniques, such 
as confocal fluorescence microscopy. If more than one cell 
type is labeled, then they are labeled with different colored 
dyes so that each cell type can be tracked independently. 
Cells are then cultured in the matrix-free culture medium in 
55 the cylindrical culture vessel during substantially horizontal 
rotation to form aggregates of the two cell types. The rate of 
substantially horizontal rotation during the aggregation phase 
is chosen so that both (1) low shear conditions are obtained; 
and (2) the osteoclast precursors and the osteoblasts are able 
60 to coalesce and form aggregates. The rate of substantially 
horizontal rotation may be selected by monitoring the cylin-
drical culture vessel and by monitoring the cells and aggre-
gates in the cylindrical culture vessel (for example using 
microscopy), to insure that the cells and aggregates are not 
65 sedimenting (which may be caused by too low a rate of 
rotation) or experiencing mechanical or excessive hydrody-
namic shear stress. In embodiments in which a HARV is used, 
US 8,557,576 B2 
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osteoclast precursors and osteoblasts may form a "boundary" 
	
The rate of substantially horizontal rotation may optionally 
layer situated in the middle of the HARV during the aggre- 	 be adjusted periodically during the further culturing phase in 
gation phase. 	 order to compensate for the increase in the sedimentation 
Preferably, the rate of substantially horizontal rotation dur- 	 pathway of the aggregates as they grow in size (and hence 
ing the aggregation phase is lower than the rate typically used 5 undergo changes in volume and density), thereby maintaining 
for culturing cells. For example, in embodiments where the 	 the growing aggregates in low shear "free fall" and preventing 
cylindrical culture vessel is a 10 mL HARV having a diameter 	 impact with the vessel wall. 
of about 10 cm and a height of about 1 cm, substantially 	 Once aggregates have attained a desired size, a matrix-free 
horizontal rotation at less than about 14 revolutions per 	 mineralization culture medium is introduced into the cylin- 
minute (rpm) may be used. More preferably, substantially io drical culture vessel and the aggregates are cultured during 
horizontal rotation at less than about 12 rpm is used. In certain 	 substantially horizontal rotation until they become mineral- 
preferred embodiments, substantially horizontal rotation at 	 ized, thereby forming the mineralized three-dimensional 
between about 1 rpm and about 4 rpm is used. In one specific 	 bone constructs of the disclosure. For example, the mineral- 
embodiment, substantially horizontal rotation at about 2 rpm 	 ization process may proceed for between about 7 days and 
is used. Note that the aforementioned rpm values are provided 15 about 21 days. Preferably, the rate of substantially horizontal 
with reference to a 10 mL HARV having the aforementioned 	 rotation during such the mineralization process is higher than 
dimensions. The rpm values will vary depending on the vol- 	 the rate during the aggregation phase, but still provides low 
ume and dimensions of the cylindrical culture vessel. The rpm 	 shear conditions in the cylindrical culture vessel. For 
values during the aggregation phase for all such vessels are 	 example, a rotation rate of between about 9 rpm and about 20 
easily determined using the aforementioned methodology. 20 rpm, preferably about 14 rpm, may be used during the min- 
Without being bound by a particular theory or mechanism, 	 eralization phase for the 10 mL HARV exemplified above. 
it is believed that the use of a matrix-free culture medium 	 The rate of substantially horizontal rotation may optionally 
allows the use of rates of rotation that are substantially lower 	 be adjusted periodically during the mineralization phase in 
than previously reported in the art for culturing mammalian 	 order to compensate for the increase in the sedimentation 
cells in a low shear stress rotating bioreactor. The use of low 25 pathway of the aggregates as they increase in mass, thereby 
rotation rates, in turn, is believed for the first time to promote 	 maintaining the mineralizing aggregates in low shear "free 
efficient association of osteoclast precursors and osteoblasts 	 fall' and preventing impact with the vessel walls. 
into aggregates, and to promote three-dimensional organiza- 	 Mineralized three-dimensional bone constructs are har- 
tion of these two cell types within the aggregates. Thus, the 	 vested once they have achieved the desired size and mass. In 
organization of the cell types within the aggregate is not 30 cylindrical culture vessels with one or more access ports, the 
constrained or influenced by an exogenous carrier material, 	 bone constructs are removed through a part. When the bone 
but rather by native cell-cell interaction. Consequently, the 	 constructs exceed the diameter of the port, the vessel is dis- 
three-dimensional organization of the osteoblasts and osteo- 	 assembled to remove the bone constructs. 
clasts is physiologically realistic. 	 Osteoclasts and osteoblasts act coordinately in the miner- 
The rate of substantially horizontal rotation may optionally 35 alization process that occurs in vivo during bone formation 
be adjusted periodically during the aggregation phase in order 	 and bone restructuring. Accordingly, the mineralized three- 
to compensate for the increase in the sedimentation velocity 	 dimensional bone constructs of the disclosure, formed by the 
(which is a function of volume and density) of the forming 	 coordinated activity of osteoblasts and osteoclasts, are physi- 
aggregates, thereby maintaining the aggregates in low shear 	 ologically realistic. 
"free fall" and preventing impact with the vessel wall. 	 40 	 As described above, the mineralized three-dimensional 
The aggregation phase proceeds for a period of time suffi- 	 bone constructs of the disclosure mimic trabecular bone in 
cient to produce the desired size of aggregates. Aggregate 	 many important aspects. The bone constructs of the disclo- 
formation may be monitored during the aggregation phase by 	 sure therefore have a great many uses in the fields of, for 
visual inspection, including through the use of microscopy. It 	 example, physiology research and development, pharmaceu- 
will be apparent from the disclosure that the size of the aggre-  45 tical research, and orthopedics. Without limitation, these 
gates is also dependent on the number of cells that are initially 	 include the direct benefit of developing a model for studying 
introduced into the cylindrical culture vessel, the length of 
	
both normal bone physiology and the pathological responses 
time allowed for aggregation, as well as the rotation rate. In 	 observed in disease states such as osteoporosis, as well as 
one example, the aggregation phase is allowed to proceed for 	 providing a highly economical platform for drug develop- 
between about 24 hours and about 48 hours. 	 50 ment as it relates to the treatment of bone diseases. 
Once aggregates of the desired size have formed, the aggre- 	 The bone constructs of the disclosure also can be used for 
gates are preferably further cultured in the cylindrical culture 	 autologous grafts. Specifically, diseased or missing bone may 
vessel during substantially horizontal rotation for a period of 
	
be replaced with ex-vivo-derived mineralized three-dimen- 
time sufficient to allow the aggregates to grow to a desired 	 sional bone constructs in which the component osteoclasts 
size through cell proliferation and/or to allow the osteoclast 55 and osteoblasts are harvested from healthy bone and periph- 
precursors in the aggregates to differentiate into osteoclasts. 	 eral blood lymphocytes of the patient requiring the bone graft. 
For example, the further culturing of the aggregates may 	 Examples of pathologies where the bone constructs of the 
proceed for between about 5 and about 7 days and may lead to 	 disclosure have therapeutic utility include fractures, non- 
grown aggregates having a diameter from between about 200 	 unions of fractures, congenital deformities of bone, bone 
µm and about 4 mm. The resultant aggregates are sometimes 60 infections, bone loss, segmental bone defects, bone tumors, 
referred to herein as "spheroids." Preferably, the rate of sub- 	 metabolic and endocrine disorders affecting bone, and tooth 
stantially horizontal rotation during the further culturing is 	 loss. 
higher than the rate during the aggregation phase, but still 
	
The bone constructs of the disclosure can also be used for 
provides low shear conditions in the cylindrical culture ves- 	 allogenic (allograft) grafts. Specifically, diseased or missing 
sel. For example, a rotation rate of between about 9 rpm and 65 bone can be replaced with ex vivo-derived mineralized three- 
about 16 rpm, preferably about 14 rpm, may be used during 	 dimensional bone constructs in which the component osteo- 
further culturing for the 10 mL HARV exemplified above. 	 clasts and osteoblasts are harvested from healthy bone and 
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peripheral blood lymphocytes of another donor for the benefit 
of a patient requiring bone graft. Examples of pathologies 
where the bone constructs of the disclosure have therapeutic 
utility include fractures, non-unions of fractures, congenital 
deformities of bone, bone infections, bone loss, segmental 
bone defects, bone tumors, metabolic and endocrine disor-
ders affecting bone, and tooth loss. 
Because the bone constructs of the disclosure closely 
resemble bone formed in vivo, it is expected that they produce 
unique factors and/or cytokines essential for bone remodel-
ing. Accordingly, the bone constructs of the disclosure serve 
as a source for identification and harvesting of these factors. 
The bone constructs of the disclosure may also be used to 
study the interface between prosthetic devices/materials and 
bone tissue. 15 
Sensors or stimulation devices may be incorporated into 
the bone constructs of the disclosure, and the resulting con-
structs implanted into bone tissue in vivo. 
The bone constructs of the disclosure also may be used in 
the production of large structures of specific dimensions for 20 
"form-fitted" applications such as replacement of large 
regions of the skeleton. This may be achieved using a com-
bination of tissue scaffolding/synthetic support materials 
embedded with numerous bone constructs to generate a much 
larger composite tissue aggregate. 25 
The bone constructs of the disclosure also provide a low 
cost alternative in which to study the effects of microgravity, 
and of other space environment insults, such as radiation, on 
the process of bone formation/bone loss. 
The following examples are not to be construed as limiting 30 
the scope of the invention disclosed herein in any way. 
EXAMPLES 
Example 1 	 35 
Flow Chart of a Method for Producing Bone 
Constructs 
A flow chart of the method for producing mineralized 40 
three-dimensional bone constructs is provided in FIG. 1. 
Osteoblast and osteoclast precursor cells are first isolated 
(110) from a healthy patient and then inoculated (120) into a 
modified High Aspect Rotating Vessel (HARV) with a 
matrix-free culture medium. Cells are allowed to aggregate 45 
(130) at a rotation speed (typically 2 rpm) much lower than 
that commonly used for the culture of mammalian cells. Low 
speed promotes aggregation of the two or more cell types in 
the early stages of aggregate formation. After the aggregation 
period is over, the rotation speed of the HighAspect Rotating 50 
Vessel is increased (140). This allows the bone construct to 
grow into spheroids (150) in a state of "free fall". The min-
eralization step (160) is then initiated by exchanging the 
initial matrix-free culture medium for a matrix-free mineral-
ization culture medium, which initiates the production of a 55 
calcified crystalline matrix in the center of the tissue aggre-
gate. The bone constructs are then characterized. The spatial 
arrangement of the different cell types is observed by confo-
cal microscopy imaging (170). The cells are visualized with 
Z-series confocal imaging (175) by pre-labeling the initial 60 
cell constituents of the construct with green fluorescent cell 
tracker probe. The presence of calcium, phosphate and car-
bonate is revealed by using Alizarin red S stain and Kossa 
histochemical stain (180), while the presence of nucleated 
cells embedded in the crystalline matrix is revealed by 65 
nuclear staining (185). Immuno-staining of the construct 
(190) shows that cell markers such as alkaline phosphate are 
Cryopreserved primary normal human osteoblast cells and 
normal human osteoclast precursor cells were purchased 
from the Cambrex Corporation (East Rutherford, N.7.) and 
stored frozen under liquid nitrogen until needed. 
Osteoblast cells were rapidly thawed by placing the vial in 
a 37° C. oven, removing the cell suspension from the vial and 
placing it in a 15 ml centrifugation tube and then diluting the 
cell suspension with 10 ml of Dulbecco's Modified Essential 
Medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum (10% FBS-DMEM). The cells were then collected by 
centrifugation at l 00xg for 5 min at 4° C. The supernatant was 
then removed and the cell pellet was resuspended by gentle 
tituration in 10 ml of fresh 10% FBS-DMEM supplemented 
with 5 µM ascorbic acid and 1 mg/ml GA-1000 (gentamicin/ 
amphotericin B mixture). This process was carried out to 
wash away the cryopreservatives in which the osteoblast cells 
had been frozen. 
The resulting cell suspension was then inoculated into a 
T-75 tissue culture flask and incubated at 37° C. in a 5% CO z 
atmosphere tissue culture incubator for a total period of seven 
days, with the medium being exchanged every three days. 
After seven days the osteoblast culture was approaching con-
fluence and the osteoblast cells were harvested by removing 
the cells from the surface of the flask using trypsin/EDTA 
digestion followed by collection of the cells by centrifugation 
as above. The cell pellet was then gently resuspended in 20 ml 
of fresh 10% FBS-DMEM supplemented with 5 µM ascorbic 
acid and 1 mg/ml GA-1000. The resulting cell suspension 
was then inoculated into two T-75 tissue culture flasks and 
again cultured for an additional seven days. This process of 
osteoblast cell expansion continued until the cells had 
reached passage 5 (i.e. five expansion/population doubling 
cycles). 
When the osteoblast cells had reached Passage 5 in culture 
they were harvested using trypsin/EDTA digestion followed 
by collection of the cells by centrifugation as above. The cell 
pellet was then gently resuspended in 10 ml of fresh 10% 
FBS-DMEM supplemented with 5 µM ascorbic acid, 100 
Ural penicillin and 100 ug/ml streptomycin, penicillin/strep-
tomycin being substituted for GA-1000 at this point due to the 
potential negative effects of gentamicin on the capability of 
osteoblast cells to produce mineralized extracellular matrix. 
The resulting osteoblast cell suspension was counted using a 
hemacytometer to ascertain the number of osteoblast cells/ 
ml. An aliquot of cell suspension containing a total of six 
million osteoblast cells was removed and placed in a separate 
15 ml centrifugation tube in preparation for the addition of 
osteoclast precursor cells. 
Osteoclast precursor cells were rapidly thawed by placing 
the vial in a 37° C. oven, removing the cell suspension from 
the vial and placing it in a 15 ml centrifugation tube and then 
diluting the cell suspension with 10 ml of Dulbecco's Modi-
fied Essential Medium (DMEM) supplemented with 10% 
(v/v) fetal bovine serum (10% FBS-DMEM). The cells were 
then collected by centrifugation at 100xg for 5 min at 4° C. 
The supernatant was then removed and the cell pellet was 
10 
absent from the cells embedded in the crystalline matrix. 
Finally, prelabeling of the osteoclast precursor cells with Cell 
Tracker-Orange (195) shows that precursor cells allowed to 
aggregate and organize under these culture conditions 
5 express the osteoclast differentiation marker, namely osteo-
calcein. 
Example 2 
10 	 Production of Bone Constructs in a HARV 
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resuspended by gentle tituration in 1 ml of fresh 10% FBS-
DMEM supplemented with 5 µM ascorbic acid, 100 U/ml 
penicillin and 100 ug/ml streptomycin. This process was car-
ried out to wash away the cryopreservatives in which the 
osteoclast cells had been frozen. 
The resulting osteoclast precursor cell suspension was 
counted using a hemacytometer to ascertain the number of 
osteoclast precursor cells/ml. An aliquot of cell suspension 
containing a total of two million osteoclast cells was removed 
and added to the 15 ml centrifuge tube containing the six 
million osteoblast cells. The volume of medium in the cen-
trifuge tube was then was adjusted to a total of 10 ml by the 
addition of fresh 10% FBS-DMEM supplemented with 5 µM 
ascorbic acid, 100 U/ml penicillin and 100 ug/ml streptomy-
cin. Finally, the 10 ml of medium containing both osteoblast 
and osteoclast cells was supplemented with 50 ng/ml mac-
rophage colony stimulating factor (M-CSF) and 50 ng/ml of 
receptor activator of NF-kB (RANK) ligand. 
The resulting osteoblast/osteoclast cell suspension was 
then inoculated into a 10 ml rotating cell culture system 
(RCCS) flask (also know as a High Aspect Ratio Vessel 
HARV) (Synthecon, Inc.) and horizontally rotated at 2 RPM 
for a period of 24 hr to allow coalescence of the osteoblast and 
osteoclast cells into a solid, three dimensional tissue con-
struct. After a period of 24 hr, the rotation speed of the HARV 
was increased to 14 RPM in order ensure that the tissue 
construct was maintained in an optimal position within the 
HARV, namely not touching or hitting the sides of the rotating 
HARV rather in a state of "free-fall" within the medium 
contained within the rotating HARV. The cell medium within 
the HARV was exchanged with 10 ml of fresh 10% FBS-
DMEM supplemented with 5 µM ascorbic acid, 100 U/ml 
penicillin, 100 ug/ml streptomycin, 50 ng/ml macrophage 
colony stimulating factor (M-CSF) and 50 ng/ml of receptor 
activator of NF-kB (RANK) ligand (a matrix-free culture 
medium) after every fourth day of culture. 
After a period of seven days of culture in the HARV under 
the above conditions the medium was exchanged for 10 ml of 
fresh 10% FBS-DMEM supplemented with 5 µM ascorbic 
acid, 100 U/ml penicillin, 100 ug/ml streptomycin, 50 ng/ml 
macrophage colony stimulating factor (M-CSF), 50 ng/ml of 
receptor activator of NF-kB (RANK) ligand, 200 µM hydro-
cortisone-21-hemisuccinate and 10 mM beta-glycerophos-
phate (a matrix-free mineralization culture medium). The 
hydrocortisone-21-hemisuccinate and beta-glycerophos-
phate were added to the medium to induce mineralization of 
the tissue construct by the osteoblasts. The cell medium 
within the HARV was exchanged with 10 ml of fresh 10% 
FBS-DMEM supplemented with 5 µM ascorbic acid, 100 
U/ml penicillin, 100 ug/ml streptomycin, 50 ng/ml macroph-
age colony stimulating factor (M-CSF), 50 ng/ml of receptor 
activator of NF-kB (RANK) ligand, 200 µM hydrocortisone-
21-hemisuccinate and 10 mM beta-glycerophosphate every 
fourth day until the tissue construct was harvested. 
Example 3 
Imaging of Bone Constructs 
The method of Example 2 was followed, with the following 
differences: primary osteoblasts and osteoclast precursors 
were mixed together at about a 2:1 ratio of osteoblasts to 
osteoclast precursors, with the total number of cells being 
about 9 million cells; the mixture of cells was then horizon-
tally rotated at 2 rpm for 48 hrs, and then at 14 rpm for 5 days; 
and mineralization proceeded at 16 rpm for 21 days. The 
resulting mineralized three-dimensional bone constructs are 
12 
pictured in FIG. 2A (at 14 days of mineralization) and FIG. 
2B (at 21 days of mineralization). The scale bar in each figure 
is 1 cm. 
5 	 Example 4 
Bone Constructs with Labeled Osteoclasts 
55 
Example 6 
Staining of Bone Constructs with Alizarin Red S, 
von Kossa, and Harris Hematoxylin Stains 
60 
Mineralized three-dimensional bone constructs were pre-
pared as detailed in Example 3. The bone constructs were then 
fixed using a Bouin's solution (a rapid penetrating fixative 
solution), frozen sectioned, and stained for calcium using the 
65 Alizarin red S stain and for phosphates and carbonates using 
the von Kossa histochemical stain. FIG. 5A shows a 5x mag-
nification image ofAlizarin red S staining and FIG. 5B shows 
The method of Example 2 was followed, withthe following 
10 differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Red probe (Invitrogen, Inc.) prior to mix-
ing with osteoblasts; primary osteoblasts and labeled osteo-
clast precursors were mixed together at about a 2:1 ratio of 
osteoblasts to osteoclast precursors, with the total number of 
15 cells being about 3 million cells; the mixture of cells was then 
horizontally rotated at 2 rpm for 24 hrs, and then at 14 rpm for 
5 days; and mineralization proceeded at 16 rpm for 14 days. 
FIG. 3A shows a fluorescence confocal microscopy image of 
an optical section through some of the resulting mineralized 
20 three-dimensional bone constructs. The results show that 
osteoclast precursor cells (observable as white spots in FIG. 
3A) have spatially arranged themselves as an outer layer of 
the mineralized three-dimensional bone constructs with the 
putative osteoblast cells being embedded in the crystalline 
matrix of the central region of the constructs. FIG. 3B shows 
25 the same constructs viewed in incident laser light (i.e. non-
fluorescent illumination) to illustrate the shape of the con-
structs. The scale bar in each of FIG. 3A and FIG. 3B is 200 
µm. 
30 	 Example 5 
Optic Sectioning of a Bone Construct with Labeled 
Osteoclasts 
35 The method of Example 2was followed, withthe following 
differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Green probe (Invitrogen, Inc.) prior to 
mixing with osteoblasts; primary osteoblasts and labeled 
osteoclast precursors were mixed together at about a 2:1 ratio 
of osteoblasts to osteoclast precursors, with the total number 
40 of cells being about 6 million cells; the mixture of cells was 
then horizontally rotated at 2 rpm for 48 hrs, and then at 14 
rpm for 5 days; and mineralization proceeded at 16 rpm for 21 
days. Three dimensional reconstruction of a resulting large 
bone construct was performed using Z series confocal imag- 
45 ing. Panels A-I in FIG. 4 are the individual images used by the 
confocal imaging software to build the optical reconstruction 
of the bone construct in three dimensions, each image repre-
senting a sequential view over the surface of the construct 
(white spots indicate individual cells). FIG. 4 indicates that 
50 the arrangement of osteoclasts to the outer layer of the con-
struct remains a feature of the construct even after extended 
culture periods (i.e. a total of four weeks in the HARV vessel, 
including three weeks grown in mineralization conditions). 
Labeled osteoclasts are apparent in an outer layer covering 
the surface of the construct. 
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a 20x magnification image of Alizarin red S staining (which 
appears as the dark regions of the images). FIG. 5C shows a 
5x magnification image of von Kossa staining and FIG. 5B 
shows a 20x magnification image of von Kossa staining 
(which appears as the dark regions of the images). The results 5 
demonstrate that the crystalline matrix of the mineralized 
three-dimensional bone constructs contain mineral elements 
observed in normal human bone in vivo. 
The same sections were also stained for the presence of 
nucleated cells using the Harris Hematoxylin stain. The io 
results are shown in FIG. 6A (5x magnification image) and 
FIG. 6B (20x magnification image). The dark regions of the 
image indicate staining. The staining pattern illustrates a 
large number of cells embedded within the crystalline matrix 
of the three dimensional construct. These cell nuclei appear 15 
intact with little or no signs of nuclear fragmentation, a his-
tological indicator of the occurrence of cell death/apoptosis. 
Arrows in FIG. 6B point to large numbers of cells embedded 
within the crystalline matrix in the three dimensional con-
struct. Cell nuclei appear intact with little or no signs of 20 
nuclear fragmentation; such fragmentation would be a histo-
logical indicator of the occurrence of cell death/apoptosis. 
Immuno-staining of these sections for the presence of osteo-
blast cell markers, such as alkaline pho sphatase, indicated the 
absence of osteoblast cell markers in the cell type embedded 25 
in the crystalline matrix. Thus, it is believed that the cells 
embedded in the crystalline matrix are osteocytes. 
Example 7 
30 
Detection of Osteocalcein, an Osteoclast 
Differentiation Marker, in Bone Constructs Using 
Immunofluorescence 
Themethodof Example 2 was followed, withthe following 35 
differences: osteoclast precursors were labeled with the fluo-
rescent CellTracker-Orange probe (Invitrogen, Inc.) prior to 
mixing with osteoblasts; primary osteoblasts and labeled 
osteoclast precursors were mixed together at about a 2:1 ratio 
of osteoblasts to osteoclast precursors, with the total number 40 
of cells being about 6 million cells; the mixture of cells was 
then horizontally rotated at 2 rpm for 48 hrs, and then at 14 
rpm for 5 days; and mineralization proceeded at 16 rpm for 21 
days. The resulting mineralized three-dimensional bone con-
structs were fixed using a phosphate buffered saline solution 45 
(pH 7.2) containing 1% (v/v) freshly generated formalde-
hyde. The fixed bone constructs were then immunochemi-
cally stained using a monoclonal antibody against osteocal-
cein (an osteoclast differentiation marker) as the primary 
antibody and an Alexa 488-labeled secondary antibody. FIG. 50 
7A-7C shows images obtained by simultaneously imaging 
both markers in one of the bone constructs using confocal 
microscopy. Specifically, FIG. 7A shows osteocalcein stain-
ing, FIG. 7B shows Celffracker-Orange staining, and FIG. 
7C shows the same construct illuminated with incident laser 55 
light. The results indicate that osteocalcein staining and Cell-
Tracker-Orange staining (both visible as a white "ring" 
around the construct in FIGS. 7A and 713) are spatially local-
ized to the same area of the construct. This indicates that the 
osteoclast precursor cells had differentiated into mature 60 
osteoclasts that were spatially localized to the surface of the 
construct. 
What is claimed is: 
1. A mineralized three-dimensional bone construct com- 
prising 	 65 
a spheroid of between about 200 µm and about 4 mm in 
diameter having an outer layer surrounding an inner  
14 
core, wherein said outer layer comprises osteoclasts, 
wherein said inner layer comprises osteoblasts, osteo-
cytes, or both osteoblasts and osteocytes embedded 
within a crystalline matrix, and wherein said crystalline 
matrix comprises calcium, phosphates, and carbonates. 
2. A mineralized three-dimensional bone construct pro-
duced by the method comprising: 
(a) introducing osteoclast precursors and osteoblasts into a 
cylindrical culture vessel that rotates about a central 
horizontal axis, said cylindrical culture vessel compris-
ing a matrix-free culture medium; 
(b) culturing said osteoblasts and said osteoclast precursors 
in said cylindrical culture vessel during horizontal rota-
tion at a rate effective to create low shear conditions and 
to promote the formation of aggregates comprising said 
osteoclast precursors and said osteoblasts; 
(c) further culturing said aggregates in said cylindrical 
culture vessel during horizontal rotation at a rate effec-
tive to create low shear conditions, whereby said aggre-
gates grow in size and said osteoclast precursors differ-
entiate into osteoclasts; and 
(d) introducing a matrix-free mineralization culture 
medium into said cylindrical culture vessel and cultur-
ing said aggregates during horizontal rotation at a rate 
effective to create low shear conditions, wherein said 
mineralized three-dimensional bone constructs are 
formed, 
wherein the mineralized three-dimensional bone construct 
comprises one or more osteocytes. 
3. The mineralized three-dimensional bone construct of 
claim 2 which is approximately spheroidal. 
4. The mineralized three-dimensional bone construct of 
claim 3 which is between about 200 µm and about 4 mm in 
diameter. 
5. The mineralized three-dimensional bone construct of 
claim 3 which comprises an outer layer surrounding an inner 
core, wherein said outer layer comprises said osteoclasts, and 
wherein said inner core comprises a crystalline matrix that 
stains positively with Alizarin Red S stain and von Kossa 
stain. 
6. A method of forming a mineralized three-dimensional 
bone comprising: 
(a) introducing osteoclast precursors and osteoblasts into a 
cylindrical culture vessel that rotates about a central 
horizontal axis, said cylindrical culture vessel compris-
ing a matrix-free culture medium; 
(b) culturing said osteoblasts and said osteoclast precursors 
in said cylindrical culture vessel during horizontal rota-
tion at a rate effective to create low shear conditions and 
to promote the formation of aggregates comprising said 
osteoclast precursors and said osteoblasts; 
(c) further culturing said aggregates in said cylindrical 
culture vessel during horizontal rotation at a rate effec-
tive to create low shear conditions, whereby said aggre-
gates grow in size and said osteoclast precursors differ-
entiate into osteoclasts; and 
(d) introducing a matrix-free mineralization culture 
medium into said cylindrical culture vessel and cultur-
ing said aggregates during horizontal rotation at a rate 
effective to create low shear conditions, wherein said 
mineralized three-dimensional bone constructs are 
formed, 
wherein the mineralized three-dimensional bone construct 
comprises one or more osteocytes. 
